Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Christine Ring Sells 5,760 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $21.43, for a total transaction of $123,436.80. Following the transaction, the insider now directly owns 24,592 shares in the company, valued at $527,006.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Christine Ring also recently made the following trade(s):

• On Monday, July 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60.
• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total transaction of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.00, for a total transaction of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total transaction of $27,147.96.

Nurix Therapeutics Stock Down 1.9 %

NASDAQ NRIX traded down $0.41 on Thursday, hitting $21.47. 540,187 shares of the stock were exchanged, compared to its average volume of 972,669. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $24.38. The company has a market cap of $1.38 billion, a PE ratio of -7.46 and a beta of 2.22. The company has a 50-day moving average price of $19.08 and a 200-day moving average price of $14.71.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Institutional Trading of Nurix Therapeutics

Several institutional investors have recently modified their holdings of the stock. Redmile Group LLC raised its position in Nurix Therapeutics by 37.7% in the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after purchasing an additional 1,226,497 shares during the last quarter. Vanguard Group Inc. raised its position in Nurix Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock valued at $21,339,000 after purchasing an additional 22,804 shares during the last quarter. Affinity Asset Advisors LLC raised its position in Nurix Therapeutics by 17.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 810,253 shares of the company’s stock valued at $11,911,000 after purchasing an additional 120,141 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Nurix Therapeutics by 9.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 622,297 shares of the company’s stock valued at $6,422,000 after purchasing an additional 53,721 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Nurix Therapeutics by 73.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 434,413 shares of the company’s stock valued at $6,386,000 after purchasing an additional 184,086 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $35.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. Stephens initiated coverage on shares of Nurix Therapeutics in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target for the company. Royal Bank of Canada lifted their price target on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. Truist Financial began coverage on shares of Nurix Therapeutics in a report on Wednesday. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Stifel Nicolaus restated a “buy” rating and issued a $27.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.